# Alto Neuroscience Announces Completion of Enrollment in Phase 2 **URL:** \ **Category:** News on schizophrenia and mental health matters\ **Created:** [February 14, 2026, 1:21am UTC](https://schizophreniasupport.discourse.group/t/alto-neuroscience-announces-completion-of-enrollment-in-phase-2/2859 "2026-02-14T01:21:13Z")\ **Posts on this page:** 2\ **Page:** 1
**Author:** ![Nirvana](https://yyz2.discourse-cdn.com/flex012/user_avatar/schizophreniasupport.discourse.group/nirvana/32/615_2.png) [@Nirvana](https://schizophreniasupport.discourse.group/u/Nirvana)\ **Post date:** [February 14, 2026, 1:21am UTC](https://schizophreniasupport.discourse.group/t/alto-neuroscience-announces-completion-of-enrollment-in-phase-2/2859/1 "2026-02-14T01:21:13Z")
> **[Alto Neuroscience Announces Completion of Enrollment in Phase 2...](https://www.biospace.com/press-releases/alto-neuroscience-announces-completion-of-enrollment-in-phase-2-proof-of-concept-study-of-alto-101-in-cognitive-impairment-associated-with-schizophrenia)** Alto Neuroscience, a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, **today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia** (CIAS). ---
**Author:** ![SzSupportAdmin](https://yyz2.discourse-cdn.com/flex012/user_avatar/schizophreniasupport.discourse.group/szsupportadmin/32/334_2.png) [@SzSupportAdmin](https://schizophreniasupport.discourse.group/u/SzSupportAdmin)\ **Post date:** [March 20, 2026, 8:52pm UTC](https://schizophreniasupport.discourse.group/t/alto-neuroscience-announces-completion-of-enrollment-in-phase-2/2859/2 "2026-03-20T20:52:56Z")